A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation for Hematological Malignancies in Adult patients
100 Clinical Results associated with O P I Products, Inc.
0 Patents (Medical) associated with O P I Products, Inc.
100 Deals associated with O P I Products, Inc.
100 Translational Medicine associated with O P I Products, Inc.